These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2510592)

  • 1. Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve.
    Tisdale JE; Pasko MT; Mylotte JM
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1500-5. PubMed ID: 2510592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum bactericidal rate as measure of antibiotic interactions.
    Briceland LL; Pasko MT; Mylotte JM
    Antimicrob Agents Chemother; 1987 May; 31(5):679-85. PubMed ID: 3111359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
    Chan E; Zhou S; Srikumar S; Duan W
    Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
    Kim A; Sutherland CA; Kuti JL; Nicolau DP
    Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.
    Bergen PJ; Bulitta JB; Kirkpatrick CM; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Lipman J; Roberts JA; Landersdorfer CB
    J Antimicrob Chemother; 2016 Sep; 71(9):2509-20. PubMed ID: 27231278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacokinetics and serum bactericidal activity of mezlocillin, ticarcillin and piperacillin, with and without gentamicin.
    Viollier AF; Standiford HC; Drusano GL; Tatem BA; Moody MR; Schimpff SC
    J Antimicrob Chemother; 1985 May; 15(5):597-606. PubMed ID: 4008387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant.
    Mentec H; Vallois JM; Bure A; Saleh-Mghir A; Jehl F; Carbon C
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1883-9. PubMed ID: 1329634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers.
    Alou L; Aguilar L; Sevillano D; Giménez MJ; Laguna B; Echeverría O; Carcas A; Lubomirov R; Casal J; Prieto J
    J Antimicrob Chemother; 2005 May; 55(5):742-7. PubMed ID: 15761068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa.
    Klepser ME; Patel KB; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2503-10. PubMed ID: 8585734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
    Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
    Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
    Burgess DS; Waldrep T
    Clin Ther; 2002 Jul; 24(7):1090-104. PubMed ID: 12182254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperacillin and gentamicin suppress Pseudomonas aeruginosa pyoderma acuta complicated by diabetes mellitus.
    Higaki S; Kitagawa T; Takashima H; Makino T; Morohashi M; Yamagishi T
    Int J Antimicrob Agents; 2004 Nov; 24(5):519-20. PubMed ID: 15519489
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
    Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
    J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Susceptibility of Pseudomonas aeruginosa to aztreonam in comparison to other pseudomonas-active beta-lactam antibiotics and gentamicin].
    Wundt W; Lange KP; Baumgärtner M
    Arzneimittelforschung; 1985; 35(8):1322-5. PubMed ID: 3935123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Studies of dosing regimens and combination effects of aminoglycosides and beta-lactam in an experimental Pseudomonas aeruginosa infection in mice].
    Kikuchi K
    Kansenshogaku Zasshi; 1991 Feb; 65(2):216-25. PubMed ID: 2066605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
    Leclercq R; Duval J
    Pathol Biol (Paris); 1995 Apr; 43(4):245-52. PubMed ID: 7567109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal and synergistic activity of moxalactam alone and in combination with gentamicin against Pseudomonas aeruginosa.
    Yu PK; Edson RS; Washington JA; Hermans PE
    Antimicrob Agents Chemother; 1983 Jan; 23(1):179-81. PubMed ID: 6219619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
    Yadav R; Rogers KE; Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.
    Kuti JL; Nightingale CH; Quintiliani R; Nicolau D
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):51-7. PubMed ID: 12376031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bactericidal activity and killing rate of serum in volunteers receiving pefloxacin alone or in combination with ceftazidime, piperacillin or mezlocillin against Pseudomonas aeruginosa.
    Van der Auwera P; Husson M; Klastersky J
    J Antimicrob Chemother; 1988 Jan; 21(1):49-55. PubMed ID: 3128521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.